COSMIC-021 Trial Shows Efficacy and Tolerability in mCRPC
Neeraj Agarwal, MD, discusses the efficacy of cabozantinib and atezolizumab in the COSMIC-021 study.
Neeraj Agarwal, MD, director of the Genitourinary Oncology Program, Oncology Division, and professor of medicine at the Huntsman Cancer Institute, University of Utah, discusses the efficacy of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in the COSMIC-021 study.
The phase Ib trial investigated patients with metastatic castration-resistant prostate cancer (mCRPC). Agarwal says that the responses from this trial have not been seen with any other combination in this setting, immunotherapy combinations or otherwise.
The median overall survival in this patient population is about 15 months, so there is an unmet need for these patients, Agarwal explains. Objective responses in the COSMIC-021 trial was 32% with the combination, and 47% of patients had stable disease, for a disease control rate of about 80%. He feels that the durability of the responses were even more remarkable. The median duration of response was 8 months.
Agarwal says that all these data make for exciting outcomes for patients with mCRPC. He thinks it is also important that the combination did not show any new safety signals. The adverse events (AEs) were mostly grade 1/2, and there were a few grade 3 AEs. Agarwal says there were no grade 4 AEs in these patients, which are older than other patient populations with other kinds of cancer.
Overall, Agarwal believes the objective responses, disease control rate, duration of responses, and high tolerability of this drug combination makes it a promising treatment regimen.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
